Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with relapsing multiple sclerosis (MS).
Results from the phase 2 study, being presented at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab significantly reduced disease activity in patients with relapsing forms of the disease.
Source: https://www.sanofi.com/en/media-room/press-releases/2023/2023-05-31-05-00-00-2678991